An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
ON FEBRUARY 3, 2024, a select multidisciplinary group of physicians
that included surgeons, radiation oncologists, and medical oncologists from
academic and community practices participated in a live workshop to discuss
current practices and recent updates on ADCs for the treatment of patients with
NSCLC. A discussion moderated by Ticiana Leal, MD, provided perspectives
and insights on approved and emerging ADCs in NSCLC including key clinical
trial data on ADC efficacy and safety, treatment selection, and strategies to
manage associated adverse events (AEs). Leal also presented patient cases
for discussion.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.